Armed with Phase III win, Incyte eyes label expansion for Monjuvi

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

Submitted by admin on August 16, 2024 - 11:19am
Source: 
Clinical Trials Arena
News Tags: 
Incyte
clinical trials
Monjuvi
relapsed or refractory follicular lymphoma
Headline: 
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
snippet: 

Incyte has announced positive topline data from the Phase III inMIND trial evaluating its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in patients with relapsed or refractory (r/r) follicular lymphoma.

Do Not Allow Advertisers to Use My Personal information